CP and hepatocellular carcinoma: The National Comprehensive Cancer Network (NCCN) Clinical Practical Guidelines in Oncology (www.nccn.org/guidelines) recommends this drug for the treatment of advanced HCC in patients with moderate liver dysfunction (i.e. CP B7).